No Data
Shandong Buchang Pharmaceuticals (603858.SH) plans to invest in the establishment of a holding subsidiary to improve its Global Strategy development layout.
Shandong Buchang Pharmaceuticals (603858.SH) released an announcement to improve its Global Strategy development layout, obtaining...
Shandong Buchang Pharmaceuticals (603858.SH): plans to establish a holding subsidiary, ShanDong Buchang Zhenze Pharmaceutical Technology Co., Ltd.
Gelonghui, January 8th丨Shandong Buchang Pharmaceuticals (603858.SH) announced that in order to improve its strategic development layout, gain market competitive advantages on the basis of segmented management, and promote Business development, it plans to invest in establishing a holding subsidiary, Shandong Buchang Zhenze Pharmaceutical Technology Co., Ltd. (registered according to industrial and commercial registration). To promote a win-win situation for the company and all parties involved, and to create maximum value for the company and its Shareholders, relevant personnel plan to participate in this investment according to the provisions of the "Investment Management Measures for Follow-up Investment Projects of Shandong Buchang Pharmaceuticals Co., Ltd.".
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
Shandong Buchang Pharmaceuticals Terminates Agreements With Nantong Lianya Pharmaceutical
Express News | Shandong Buchang Pharmaceuticals: plans to sign a "Development, Supply and Sales Termination Agreement" with Nantong Lianya.
Express News | Shandong Buchang Pharmaceuticals: plans to repurchase shares for 50 million to -0.1 billion yuan.
No Data